AMNEAL PHARMACEUTICALS, INC. Research and Development Expense
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Research and Development Expense of $39.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $39.02M, a 18.65% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $38.38M, a 4.14% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $34.82M, a 35.84% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $63.35M, a 3.69% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $186.18M, a 2.38% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $190.71M, a 16.32% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $163.95M, a 16.22% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $195.69M, a 3.05% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $39.02M 10-Q · filed 2026-08-06 | $77.40M 10-Q · filed 2026-08-06 | $112.22M derived: sum of 3 quarters · filed 2026-08-06 | $175.57M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $38.38M 10-Q · filed 2026-05-07 | $73.20M derived: sum of 2 quarters · filed 2026-05-07 | $136.55M derived: sum of 3 quarters · filed 2026-05-07 | $184.52M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $34.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $98.17M derived: sum of 2 quarters · filed 2026-02-27 | $146.13M derived: sum of 3 quarters · filed 2026-08-06 | $186.18M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $63.35M 10-Q · filed 2025-11-06 | $111.32M derived: sum of 2 quarters · filed 2026-08-06 | $151.36M 10-Q · filed 2025-11-06 | $205.62M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $47.96M 10-Q · filed 2026-08-06 | $88.00M 10-Q · filed 2026-08-06 | $142.27M derived: sum of 3 quarters · filed 2026-08-06 | $203.37M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $40.04M 10-Q · filed 2026-05-07 | $94.31M derived: sum of 2 quarters · filed 2026-05-07 | $155.40M derived: sum of 3 quarters · filed 2026-05-07 | $191.46M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $54.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $115.36M derived: sum of 2 quarters · filed 2026-02-27 | $151.42M derived: sum of 3 quarters · filed 2026-02-27 | $190.71M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $61.10M 10-Q · filed 2025-11-06 | $97.15M derived: sum of 2 quarters · filed 2025-11-06 | $136.45M 10-Q · filed 2025-11-06 | $182.53M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $36.05M 10-Q · filed 2025-08-07 | $75.35M 10-Q · filed 2025-08-07 | $121.44M derived: sum of 3 quarters · filed 2026-02-27 | $162.81M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $39.30M 10-Q · filed 2025-05-07 | $85.38M derived: sum of 2 quarters · filed 2026-02-27 | $126.76M derived: sum of 3 quarters · filed 2026-02-27 | $164.56M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $46.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $87.46M derived: sum of 2 quarters · filed 2026-02-27 | $125.26M derived: sum of 3 quarters · filed 2026-02-27 | $163.95M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $41.38M 10-Q · filed 2024-11-12 | $79.17M derived: sum of 2 quarters · filed 2024-11-12 | $117.86M 10-Q · filed 2024-11-12 | $159.77M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $37.80M 10-Q · filed 2024-08-09 | $76.49M 10-Q · filed 2024-08-09 | $118.40M derived: sum of 3 quarters · filed 2025-02-28 | $168.63M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $38.69M 10-Q · filed 2024-05-08 | $80.60M derived: sum of 2 quarters · filed 2025-02-28 | $130.83M derived: sum of 3 quarters · filed 2025-02-28 | $181.58M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | $41.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $92.14M derived: sum of 2 quarters · filed 2025-02-28 | $142.89M derived: sum of 3 quarters · filed 2025-02-28 | $195.69M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $50.23M 10-Q · filed 2023-11-09 | $100.98M derived: sum of 2 quarters · filed 2023-11-09 | $153.78M 10-Q · filed 2023-11-09 | $205.66M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $50.75M 10-Q · filed 2023-08-08 | $103.55M 10-Q · filed 2023-08-08 | $155.42M derived: sum of 3 quarters · filed 2024-03-14 | $204.35M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $52.80M 10-Q · filed 2023-05-09 | $104.67M derived: sum of 2 quarters · filed 2024-03-14 | $153.60M derived: sum of 3 quarters · filed 2024-03-14 | $206.46M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | $51.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $100.80M derived: sum of 2 quarters · filed 2024-03-14 | $153.66M derived: sum of 3 quarters · filed 2024-03-14 | $201.85M 10-K · filed 2024-03-14 | ||
| 2021-09-30 | $48.93M 10-Q · filed 2022-11-07 | $101.79M derived: sum of 2 quarters · filed 2022-11-07 | $149.97M 10-Q · filed 2022-11-07 | $203.43M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-06-30 | $52.86M 10-Q · filed 2022-08-08 | $101.05M 10-Q · filed 2022-08-08 | $154.51M derived: sum of 3 quarters · filed 2023-03-03 | $199.03M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-03-31 | $48.18M 10-Q · filed 2022-05-06 | $101.64M derived: sum of 2 quarters · filed 2023-03-03 | $146.16M derived: sum of 3 quarters · filed 2023-03-03 | $191.73M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2020-12-31 | $53.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $97.98M derived: sum of 2 quarters · filed 2023-03-03 | $143.55M derived: sum of 3 quarters · filed 2023-03-03 | $179.93M 10-K · filed 2023-03-03 | ||
| 2020-09-30 | $44.52M 10-Q · filed 2021-11-08 | $90.09M derived: sum of 2 quarters · filed 2021-11-08 | $126.47M 10-Q · filed 2021-11-08 | $174.52M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $45.57M 10-Q · filed 2021-08-09 | $81.95M 10-Q · filed 2021-08-09 | $130.00M derived: sum of 3 quarters · filed 2022-03-01 | $168.13M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $36.38M 10-Q · filed 2021-05-07 | $84.43M derived: sum of 2 quarters · filed 2022-03-01 | $122.55M derived: sum of 3 quarters · filed 2022-03-01 | $170.57M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $48.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $86.17M derived: sum of 2 quarters · filed 2022-03-01 | $134.19M derived: sum of 3 quarters · filed 2022-03-01 | $188.05M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $38.13M 10-Q · filed 2020-11-06 | $86.14M derived: sum of 2 quarters · filed 2020-11-06 | $140.00M 10-Q · filed 2020-11-06 | $197.30M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $48.02M 10-Q · filed 2020-08-06 | $101.87M 10-Q · filed 2020-08-06 | $159.17M derived: sum of 3 quarters · filed 2021-03-01 | $201.52M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | $53.86M 10-Q · filed 2020-05-11 | $111.16M derived: sum of 2 quarters · filed 2021-03-01 | $153.50M derived: sum of 3 quarters · filed 2021-03-01 | $203.84M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $57.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $99.65M derived: sum of 2 quarters · filed 2021-03-01 | $149.98M derived: sum of 3 quarters · filed 2021-03-01 | $194.19M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $42.35M 10-Q · filed 2019-11-07 | $43.00M 10-Q · filed 2018-11-07 | $92.68M derived: sum of 2 quarters · filed 2019-11-07 | $136.89M 10-Q · filed 2019-11-07 | $137.54M 10-Q · filed 2018-11-07 | $180.39M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $50.34M 10-Q · filed 2019-08-05 | $94.54M 10-Q · filed 2019-08-05 | $138.04M derived: sum of 3 quarters · filed 2020-03-02 | $179.36M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $44.21M 10-Q · filed 2019-05-09 | $87.70M derived: sum of 2 quarters · filed 2020-03-02 | $129.03M derived: sum of 3 quarters · filed 2020-03-02 | $176.21M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $43.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $84.82M derived: sum of 2 quarters · filed 2020-03-02 | $132.00M derived: sum of 3 quarters · filed 2020-03-02 | $171.42M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $41.32M 10-Q · filed 2018-11-07 | $88.51M derived: sum of 2 quarters · filed 2018-11-07 | $127.93M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $47.18M 10-Q · filed 2018-08-09 | $86.60M 10-Q · filed 2018-08-09 | ||||
| 2016-12-31 | $179.02M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |